PharmaShots | Incisive News in 3 Shots

Subscribe Now

UC

Galapagos Reports New Post-Hoc Analyses from P-III SELECTION Program of Filgotinib to Treat Ulcerative Colitis

Galapagos Reports New Post-Hoc Analyses from P-III SELECTION Program of Filgotinib to Treat Ulcerative Colitis

July 12, 2021

AbbVie Report Results of Rinvoq (upadacitinib) in P-III Maintenance Study for the Treatment of Ulcerative Colitis

AbbVie Report Results of Rinvoq (upadacitinib) in P-III Maintenance Study for the Treatment of Ulcerative Colitis

June 30, 2021

Astellas and Seagen Report Updated Results of Padcev in Two Studies for Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy

Astellas and Seagen Report Updated Results of Padcev in Two Studies for Locally Advanced or Metastatic Urothelial Cancer Not Eligi...

May 21, 2021

Roche and Basilea Sign a Research Collaboration to Evaluate Derazantinib + Tecentriq (atezolizumab) in Patients with Urothelial Cancer (UC)

Roche and Basilea Sign a Research Collaboration to Evaluate Derazantinib + Tecentriq (atezolizumab) in Patients with Urothelial Ca...

January 25, 2019

Janssen (J&J) Reports Filing of Stelara's (ustekinumab) in Group Type II Variation Application to EMA for Moderately to Severely Active Ulcerative Colitis (UC)

Janssen (J&J) Reports Filing of Stelara's (ustekinumab) in Group Type II Variation Application to EMA for Moderately to Severe...

January 9, 2019

Sandoz's Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment of Chronic Autoimmune Diseases

Sandoz's Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment of Chronic Autoimmune Diseases

October 31, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us